David Lane (biologist)

Sir David Philip Lane (born 1 July 1952) is a British immunologist, molecular biologist and cancer researcher. He is currently working in the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institute and is [https://chugai-pharmabody.com/about/meet-our-chairman/ Chairman of Chugai Pharmabody]. He is best known for the discovery of p53, one of the most important tumour suppressor genes. Provided by Wikipedia
Showing 1 - 20 results of 31 for search 'David P. Lane', query time: 0.07s Refine Results
  1. 1
    Mapping the structural and dynamical features of multiple p53 DNA binding domains: insights into loop 1 intrinsic dynamics.

    Mapping the structural and dynamical features of multiple p53 DNA binding domains: insights into loop 1 intrinsic dynamics. by Suryani Lukman, David P Lane, Chandra S Verma

    Published 2013-01-01
    Get full text
    Article
  2. 2
    An Automated Quantification Tool for Angiogenic Sprouting From Endothelial Spheroids

    An Automated Quantification Tool for Angiogenic Sprouting From Endothelial Spheroids by Pavitra Kannan, Martin Schain, David P. Lane

    Published 2022-04-01
    Get full text
    Article
  3. 3
    Can Glycosylation Mask the Detection of MHC Expressing p53 Peptides by T Cell Receptors?

    Can Glycosylation Mask the Detection of MHC Expressing p53 Peptides by T Cell Receptors? by Thanh Binh Nguyen, David P. Lane, Chandra S. Verma

    Published 2021-07-01
    Get full text
    Article
  4. 4
    Stapled BH3 peptides against MCL-1: mechanism and design using atomistic simulations.

    Stapled BH3 peptides against MCL-1: mechanism and design using atomistic simulations. by Thomas L Joseph, David P Lane, Chandra S Verma

    Published 2012-01-01
    Get full text
    Article
  5. 5
    Targeting ATM pathway for therapeutic intervention in cancer

    Targeting ATM pathway for therapeutic intervention in cancer by Hilal S Khalil, Hemanth Tummala, Stoyan Chakarov, Nikolai Zhelev, David P. Lane

    Published 2012-07-01
    Get full text
    Article
  6. 6
    Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly

    Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly by Yuri Frosi, Rachael Usher, Dawn Thean Gek Lian, David P. Lane, Christopher J. Brown

    Published 2019-05-01
    Get full text
    Article
  7. 7
    Improved eIF4E binding peptides by phage display guided design: plasticity of interacting surfaces yield collective effects.

    Improved eIF4E binding peptides by phage display guided design: plasticity of interacting surfaces yield collective effects. by Weizhuang Zhou, Soo T Quah, Chandra S Verma, Yun Liu, David P Lane, Christopher J Brown

    Published 2012-01-01
    Get full text
    Article
  8. 8
    Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2

    Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2 by Anja C. L. Mortensen, Eric Morin, Christopher J. Brown, David P. Lane, Marika Nestor

    Published 2020-04-01
    Get full text
    Article
  9. 9
    p53-Mediated Radiosensitization of <sup>177</sup>Lu-DOTATATE in Neuroblastoma Tumor Spheroids

    p53-Mediated Radiosensitization of <sup>177</sup>Lu-DOTATATE in Neuroblastoma Tumor Spheroids by Sara Lundsten, Hanna Berglund, Preeti Jha, Cecilia Krona, Mehran Hariri, Sven Nelander, David P. Lane, Marika Nestor

    Published 2021-11-01
    Get full text
    Article
  10. 10
    A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein–protein interactions identifies a novel putative Mdm2-binding site in p53

    A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein–protein interactions identifies a novel putative Mdm2-binding site in p53 by Jin Huei Wong, Mohammad Alfatah, Mei Fang Sin, Hong May Sim, Chandra S. Verma, David P. Lane, Prakash Arumugam

    Published 2017-11-01
    Get full text
    Article
  11. 11
    Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks

    Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks by Sara Lundsten, Víctor Agmo Hernández, Lars Gedda, Tina Sarén, Christopher J. Brown, David P. Lane, Katarina Edwards, Marika Nestor

    Published 2020-04-01
    Get full text
    Article
  12. 12
    A general approach to protein folding using thermostable exoshells

    A general approach to protein folding using thermostable exoshells by Samira Sadeghi, Siddharth Deshpande, Girish Vallerinteavide Mavelli, Alphan Aksoyoglu, Jayesh Bafna, Mathias Winterhalter, R. Manjunatha Kini, David P. Lane, Chester L. Drum

    Published 2021-09-01
    Get full text
    Article
  13. 13
    MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors

    MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors by Katrine Ingelshed, Marit M. Melssen, Pavitra Kannan, Arun Chandramohan, Anthony W. Partridge, Long Jiang, Fredrik Wermeling, David P. Lane, Marika Nestor, Diana Spiegelberg

    Published 2024-06-01
    Get full text
    Article
  14. 14
    MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia

    MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia by Ada Lerma Clavero, Paula Lafqvist Boqvist, Katrine Ingelshed, Cecilia Bosdotter, Saikiran Sedimbi, Long Jiang, Fredrik Wermeling, Borivoj Vojtesek, David P. Lane, Pavitra Kannan

    Published 2023-03-01
    Get full text
    Article
  15. 15
    A druggable conformational switch in the c-MYC transactivation domain

    A druggable conformational switch in the c-MYC transactivation domain by Dilraj Lama, Thibault Vosselman, Cagla Sahin, Judit Liaño-Pons, Carmine P. Cerrato, Lennart Nilsson, Kaare Teilum, David P. Lane, Michael Landreh, Marie Arsenian Henriksson

    Published 2024-02-01
    Get full text
    Article
  16. 16
    Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids.

    Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids. by Sharon Min Qi Chee, Jantana Wongsantichon, Jiawei Siau, Dawn Thean, Fernando Ferrer, Robert C Robinson, David P Lane, Christopher J Brown, Farid J Ghadessy

    Published 2017-01-01
    Get full text
    Article
  17. 17
    Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.

    Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2. by Sharon Min Qi Chee, Jantana Wongsantichon, Quah Soo Tng, Robert Robinson, Thomas L Joseph, Chandra Verma, David P Lane, Christopher J Brown, Farid J Ghadessy

    Published 2014-01-01
    Get full text
    Article
  18. 18
    Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine

    Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine by Le-Ann Hwang, Beng Hooi Phang, Oi Wah Liew, Jabed Iqbal, Xiao Hui Koh, Xin Yu Koh, Rashidah Othman, Yuezhen Xue, A. Mark Richards, David P. Lane, Kanaga Sabapathy

    Published 2018-01-01
    Get full text
    Article
  19. 19
    Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine

    Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine by Le-Ann Hwang, Beng Hooi Phang, Oi Wah Liew, Jabed Iqbal, Xiao Hui Koh, Xin Yu Koh, Rashidah Othman, Yuezhen Xue, A. Mark Richards, David P. Lane, Kanaga Sabapathy

    Published 2021-08-01
    Get full text
    Article
  20. 20
    Constitutive activation of WASp leads to abnormal cytotoxic cells with increased granzyme B and degranulation response to target cells

    Constitutive activation of WASp leads to abnormal cytotoxic cells with increased granzyme B and degranulation response to target cells by Joanna S. Kritikou, Mariana M.S. Oliveira, Julien Record, Mezida B. Saeed, Saket M. Nigam, Minghui He, Marton Keszei, Arnika K. Wagner, Hanna Brauner, Anton Sendel, Saikiran K. Sedimbi, Stamatina Rentouli, David P. Lane, Scott B. Snapper, Klas Kärre, Peter Vandenberghe, Jordan S. Orange, Lisa S. Westerberg

    Published 2021-03-01
    Get full text
    Article

Search Tools: